CHEPLAPHARM Arzneimittel GmbH


This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.


Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit


The latest from CHEPLAPHARM

CHEPLAPHARM strengthens its relationship with AstraZeneca by acquiring the global commercial rights to LOSEC®

AstraZeneca has agreed to sell the global commercial rights - excluding China, Japan, the U.S. and Mexico - to LOSEC® (omeprazole) and associated brands to CHEPLAPHARM. This is CHEPLAPHARM’s first acquisition of another well-known branded global product in 2019.

Ruud Dobber, Executive Vice President at AstraZeneca: “We already have an excellent relationship with CHEPLAPHARM, whose strong European presence and global distribution network will help ensure continued patient access to LOSEC®.”
“This agreement strengthens our relationship with AstraZeneca even further“, said CHEPLAPHARM’s CEO Sebastian F. Braun. “Additionally, it matches perfectly with our internationally oriented business strategy, as CHEPLAPHARM can realize and further develop its ambitious growth strategy in the respective territories by enhancing the diversification of the country portfolios. Furthermore, this investment already contributes a significant part to our operating income in the fourth quarter of 2019.”

About LOSEC®
LOSEC® is a proton pump inhibitor discovered and developed by AstraZeneca, which helps to reduce the amount of acid produced by the stomach in patients with gastrointestinal reflux conditions and ulcers. It has a number of approved indications and is commonly prescribed for patients with gastro oesophageal reflux disease.

Press Office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)

Investor Relations topics

Back to top expand_less